Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Iberdomide, Daratumumab and Dexamethasone VS Daratumumab, Bortezomib, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma EXCALIBER RRMM

What's the purpose of this trial?

The goal of this clinical trial is to find the optimal dose of investigational drug iberdomide in combination with daratumumab and dexamethasone, and to study whether investigational drug iberdomide works in treating relapsed or refractory multiple myeloma when combined with daratumumab and dexamethasone.

This trial is currently open and accepting patients.

What will happen during the trial?

Participants in this stage will be randomly assigned into one of four groups. Three of the groups will receive different doses of investigational drug Iberdomide in combination with Daratumumab and Dexamethasone. One group will receive comparator combination of Daratumumab, Bortezomib, and Dexamethasone. The three Iberdomide groups will receive different doses of investigational drug Iberdomide.

Participants in this stage will be randomized into one of two groups. Group A will receive investigational drug Iberdomide (at the dose selected by stage 1), Daratumumab, and Dexamethasone. Group B will receive the comparator combination of Daratumumab, Bortezomib, and Dexamethasone. 

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

  • have measurable disease as defined by the trial criteria.
  • have received one to two prior lines of anti-myeloma therapy.
  • have achieved a partial response or better to at least one prior anti-myeloma regimen.
  • have not previously received treatment with a CD-38 directed therapy (for Stage 1 participants). For Stage 2 participants, previous CD-38 therapy is allowed if while receiving it you:
    • achieved at least a partial response,
    • your myeloma did not progress while receiving it, 
    • and your last dose of Daratumumab was more than three months prior to joining the study.
  • Previous treatment with Bortezomib is allowed as long as you:
    • achieved at least a minimal response, and 
    • you did not progress while receiving Bortezomib or within 60 days of your last dose.
  • do not have central nervous system involvement of your myeloma.
  • have not previously received treatment with investigational drug Iberdomide.
  • have not previously received an allogeneic stem cell transplant, and have not received an autologous stem cell transplant in the last three months.
  • have adequate bone marrow, liver, cardiac and lung function as described in the trial criteria.

Additional eligibility criteria apply and can be explained by the study doctor. 

Additional Trial Information

Phase 3

Enrollment: 864 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


Genesis Cancer and Blood Institute American Oncology Partners

Hot Springs, AR

Open and Accepting


Compassionate Cancer Care - Corona

Corona, CA

Not Yet Accepting

Compassionate Cancer Care

Fountain Valley, CA

Not Yet Accepting


Yale Cancer Center Smilow Cancer Hospital at Yale-New Haven

New Haven, CT

Open and Accepting


Boca Raton Clinical Research (BRCR) Medical Center

Plantation, FL

Not Yet Accepting


Winship Cancer Institute Emory University

Atlanta, GA

Open and Accepting


Norton Cancer Institute (St. Matthews) St. Matthews Campus

Louisville, KY

Not Yet Accepting


Christus St. Frances Cabrini Hospital

Alexandria, LA

Not Yet Accepting

Our Lady of the Lake Regional Medical Center

Baton Rouge, LA

Not Yet Accepting



Dana-Farber Cancer Institute (Main)

Boston, MA

Not Yet Accepting

University of Massachusetts Medical School

Worcester, MA

Open and Accepting


HCA Midwest Health Research Medical Center

Kansas City, MO

Open and Accepting


SCL Health St. Vincent Healthcare SCL Health

Billings, MT

Not Yet Accepting

North Carolina

Duke Cancer Center Duke University Medical Center

Durham, NC

Open and Accepting


TriHealth Bethesda North Hospital

Cincinnati, OH

Open and Accepting

MetroHealth Medical Center

Cleveland, OH

Open and Accepting

Cleveland Clinic - Taussig Cancer Center Taussig Cancer Institute

Cleveland, OH

Open and Accepting

OhioHealth Grant Medical Center

Columbus, OH

Open and Accepting


Oklahoma Cancer Specialists and Research Institute (Tulsa)

Tulsa, OK

Not Yet Accepting


Oregon Health and Science University OHSU Knight Cancer Institute

Portland, OR

Not Yet Accepting


Penn State Hershey Medical Center

Hershey, PA

Not Yet Accepting


Tennessee Oncology Memorial Plaza

Chattanooga, TN

Open and Accepting


Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors